Retrospective Evaluation of Nivolumab in Adjuvant Esophageal Cancer/Gastroesophageal Junction Cancer

Conditions

• Esophageal Cancer
• Gastroesophageal Junction Cancer

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Nivolumab — DRUG
  As per product label, as prescribed by treating physician

Study Details

The purpose of this study is to describe the real-world effectiveness and patterns of use of adjuvant nivolumab in adult participants with Stage II/III Esophageal Cancer/Gastroesophageal Junction Cancer (EC/GEJC) in China.

Key Dates

First listed

Jul 12, 2024

Start date

Dec 3, 2024

Status verified

May 2025

Primary completion

Apr 16, 2025

Completion

Apr 16, 2025

Study Design

Enrollment

64 participants (actual)

Arms

• Arm: Participants receiving adjuvant nivolumab

Primary Outcome Measure

Participant disease-free survival (DFS) [ Time Frame: Up to 1 year ]

Find similar trials

Related Studies

• Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of Life
  Recruiting · University of Pittsburgh · Pittsburgh, Pennsylvania
• Esophageal Cancer Risk Registry
  Recruiting · University of Pittsburgh · Pittsburgh, Pennsylvania
• Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients
  Recruiting · Vanderbilt University Medical Center · Nashville, Tennessee
• Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
  Recruiting · University of Colorado, Denver · Aurora, Colorado